<DOC>
	<DOCNO>NCT00915577</DOCNO>
	<brief_summary>Determine patient satisfaction single-use autoinjector delivery pre-filled Avonex syringe .</brief_summary>
	<brief_title>Patient Satisfaction Study Single-Use Autoinjector Delivery Pre-Filled Avonex Syringe</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Must use liquid AVONEX® treat MS . In addition , subject must liquid AVONEX® 12 week prior Screening Visit . Must BMI 19 28 kg/m² , inclusive , minimum body weight 50 kg Screening . Must able physically demonstrate use device able selfadminister injection . Must English speaking . Must able understand comply protocol . Abnormal screen screen blood test determine clinically significant investigator : white blood count ( WBC ) differential , platelet count , hemoglobin , serum creatinine , bilirubin , alanine transaminase ( ALT ) aspartate transaminase ( AST ) , prothrombin time ( PT ) . Known sensitivity dry natural rubber . Treatment agent treat MS symptom underlie disease specify protocol . History severe allergic anaphylactic reaction . History intolerance acetaminophen ( paracetamol ) , ibuprofen , naproxen , aspirin would preclude use least one study . Serious local infection Other inclusion exclusion criterion apply per Biogen Idec Protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>interferon beta-1a</keyword>
	<keyword>Avonex</keyword>
	<keyword>liquid Avonex</keyword>
</DOC>